Eleonora Pelle

Eleonora Pelle

Auto-generated profile, based on publicly available information

Eleonora Pelle

Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute 1

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2022 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
BMBarbara Mandriani
Barbara Mandriani
EPEleonora Pellè
Eleonora Pellè
FMFrancesco Mannavola
Francesco Mannavola
APAntonio Palazzo
Antonio Palazzo
RMRené Marsano
René Marsano
MCMauro Cives
Mauro Cives
Background Neuroendocrine tumors (NETs) overexpress somatostatin receptors (SSTRs). Methods We developed a second-generation, ligand-based, anti-SSTR chimeric antigen receptor (CAR) incorporating the somatostatin analog octreotide in its extracellular moiety. Results Anti-SSTR CAR T cells exerted antitumor activity against SSTR+NET cell linesin vitro. The killing activity was highly specific, as demonstrated by the lack of CAR T cell reactivity against NET cells engineered to express mutated variants of SSTR2/5 by CRISPR/Cas9. When adoptively transferred in NSG mice, anti-SSTR CAR T cells induced significant antitumor activity against human NET xenografts. Although anti-SSTR CAR T cells could recognize the murine SSTRs as shown by their killing ability against murine NET cells, no obvious deleterious effects on SSTR-expressing organs such as the brain or the pancreas were observed in mice. Conclusions Taken together, our results establish anti-SSTR CAR T cells as a potential candidate for early phase clinical investigations in patients with NETs. More broadly, the demonstration that a known peptide drug can direct CAR T cell targeting may streamline the potential utility of multiple peptide motifs and provide a blueprint for therapeutic applications in a variety of cancers.

1 January 2025 in Endocrine Oncology
Verified
Journal Article
Open access
EPEleonora Pelle
Eleonora Pelle
TATaymeyah Al-Toubah
Taymeyah Al-Toubah
GEGhassan El-Haddad
Ghassan El-Haddad
BMBrian Morse
Brian Morse
BKBhavana Konda
Bhavana Konda
Jonathan StrosbergJonathan Strosberg
Jonathan Strosberg
Background: Lutetium-177 (177Lu)-DOTATATE is an effective treatment for metastatic gastroenteropancreatic (GEP) NETs. However, radiation can cause transient inflammation/swelling of tumors, which can result in toxicity. Treatment-related small bowel obstruction associated with mesenteric or peritoneal disease has been described. We investigated the potential for intestinal ischemia in 177Lu-DOTATATE-treated patients. Methods: Clinical records were reviewed of patients with midgut NETs treated with 177Lu-DOTATATE at the Moffitt Cancer Center between April 2018 and December 2022 and at The Ohio State University between December 2017 and October 2020. Results: Among the cases reviewed, we identified three patients who developed bowel ischemia/perforation shortly after their initial treatment with 177Lu-DOTATATE. All patients had metastatic small bowel NET with prominent mesenteric mass encasing/obstructing the mesenteric vessels and preexisting symptoms of postprandial abdominal pain. Conclusion: Acute bowel ischemia may be a rare complication of PRRT in patients with mesenteric arterial or venous obstruction from mesenteric metastasis.